TheraRadar
Data updated: Jun 28, 2026

ORTHO TRI-CYCLEN 21 (ethinyl estradiol) · Johnson & Johnson

Women's Health Approved 2005-05-13

Ortho Tri-Cyclen 21 is a combination oral contraceptive (COC) indicated for use by females of reproductive potential to prevent pregnancy. It contains two specific hormones: norgestimate (a progestin) and ethinyl estradiol (an estrogen). As a triphasic regimen, it provides varying strengths of these hormones over a 21-day cycle to manage reproductive health and prevent conception.

How ORTHO TRI-CYCLEN 21 Works

Ortho Tri-Cyclen 21 prevents pregnancy primarily by suppressing ovulation through the inhibition of gonadotropin secretion. Secondary mechanisms include changes in cervical mucus, which increase the difficulty of sperm migration into the uterus, and alterations in the endometrium, which may reduce the likelihood of implantation.

1
Indication
--
Phase 3 Trials
1
Priority Reviews
21
Years on Market

Details

Status
Prescription
First Approved
2005-05-13
Routes
ORAL-21
Dosage Forms
TABLET

Companies

Active Ingredient: ETHINYL ESTRADIOL , NORGESTIMATE

ORTHO TRI-CYCLEN 21 Approval History

2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2005 to 2015
May 2015 SUPPL
Label · Labeling
May 2005 ORIGINAL Priority
Update · Type 6 - New Indication (no longer used)

What ORTHO TRI-CYCLEN 21 Treats

1 indications

ORTHO TRI-CYCLEN 21 is approved for 1 conditions since its original approval in 2005. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

ORTHO TRI-CYCLEN 21 Boxed Warning

CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including Iclevia, are contraindicated in women who are over 35 years of age and smoke [see Contraindications (4) and Warnings and Precautions (5.1) ]. WARNING: CIGARETTE SMOKING AND SERIOUS C...

ORTHO TRI-CYCLEN 21 Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to ORTHO TRI-CYCLEN 21

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMABELZ
ESTRADIOL
1 shared
Lupin
Shared indications:
ANNOVERA
ETHINYL ESTRADIOL
1 shared
MAYNE PHARMA INC
Shared indications:
ASHLYNA
ETHINYL ESTRADIOL
1 shared
GLENMARK PHARMS LTD
Shared indications:
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT07340190 CDAK539A12102 2025-521000-22-00 Ph 1 recruiting A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
NCT06039826 18533 J1I-MC-GZBV Ph 1 completed A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ORTHO TRI-CYCLEN 21 FDA Label Details

Indications & Usage

FDA Label (PDF)

Iclevia TM (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. Iclevia is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy.

⚠️ BOXED WARNING

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For th...

Track ORTHO TRI-CYCLEN 21 with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.